RPTP
Raptor Pharmaceutical Corp.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Thu, Oct. 20, 8:28 AM
    • Horizon Pharma plc (NASDAQ:HZNP) prices its offering of $300M aggregate principal amount of 8.75% Senior Notes due 2024. Closing date is October 25.
    • Net proceeds will help fund the Raptor Pharmaceuticals (NASDAQ:RPTP) acquisition.
    | Thu, Oct. 20, 8:28 AM
  • Fri, Sep. 16, 12:07 PM
    • C.R. Bard (NYSE:BCR) upgraded to Outperform from Market Perform by Wells Fargo.
    • DexCom (NASDAQ:DXCM) upgraded to Buy from Hold by Desjardins. Downgraded to Neutral from Buy with a $92 (1% downside risk) price target by BTIG Research.
    • Alimera Sciences (NASDAQ:ALIM) upgraded to Outperform from Market Perform by Cowen & Company.
    • Seattle Genetics (NASDAQ:SGEN) upgraded to Neutral from Sell by Goldman Sachs. Price target raised to $47 (13% downside risk) from $30.
    • Akorn (NASDAQ:AKRX) upgraded to Overweight from Neutral by Piper Jaffray. Price target raised to $34 (19% upside) from $33.
    • Community Health Systems (NYSE:CYH) upgraded to Positive from Neutral by Susquehanna. Price target raised to $18 (66% upside).
    • AstraZeneca (NYSE:AZN) upgraded to Buy from Hold by Jefferies. Price target raised to GBX 5,800 (14% upside) from GBX 5,400. Downgraded to Neutral from Outperform with a GBX 5,200 (2% upside) price target by BNP Paribas.
    • McKesson (NYSE:MCK) downgraded to Neutral from Buy by Goldman Sachs. Price target lowered to $189 (15% upside) from $210.
    • Cardinal Health (NYSE:CAH) downgraded to Neutral from Buy by Goldman Sachs. Price target lowered to $83 (8% upside) from $90.
    • Novavax (NASDAQ:NVAX) downgraded to Neutral from Outperform by Wedbush. Price target lowered to $2 (44% upside) from $14. Downgraded to Neutral from Buy by Citigroup. Price target lowered to $1.50 (8% upside) from $12. Downgraded to Neutral from Overweight by JPMorgan and Piper Jaffray.
    • Raptor Pharmaceutical (NASDAQ:RPTP) downgraded to Market Perform from Outperform by Cowen & Company.
    • Vitae Pharmaceuticals (NASDAQ:VTAE) downgraded to Market Perform from Outperform by BMO Capital.
    • Atara Biotherapeutics (NASDAQ:ATRA) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to $16 (18% downside risk) from $23.
    • GlaxoSmithKline (NYSE:GSK) downgraded to Underperform from Neutral with a GBX 1,520 (6% downside risk) price target by BNP Paribas.
    • Applied Genetic Technologies (NASDAQ:AGTC) downgraded to Neutral from Buy by Roth Capital. Price target lowered to $12 (34% upside) from $34. Downgraded to Hold from Buy by Cantor Fitzgerald. Price target lowered to $15 (68% upside) from $32.
    • Cepheid (NASDAQ:CPHD) downgraded to Neutral from Outperform by Baird.
    | Fri, Sep. 16, 12:07 PM | 8 Comments
  • Mon, Sep. 12, 12:47 PM
    | Mon, Sep. 12, 12:47 PM
  • Mon, Sep. 12, 11:00 AM
    | Mon, Sep. 12, 11:00 AM
  • Mon, Sep. 12, 9:15 AM
    | Mon, Sep. 12, 9:15 AM
  • Mon, Sep. 12, 7:32 AM
    • Horizon Pharma (NASDAQ:HZNP) acquires Raptor Pharmaceuticals (NASDAQ:RPTP) for $9 a share in cash ($800M). The deal, to be  financed with debt and cash, should close in Q4.
    • Raptor's leading products are PROCYSBI (cysteamine bitartrate) delay-release capsules for the treatment of a rare metabolic disorder called nephropathic cystinosis and QUINSAIR (aerosolized levofloxacin) for the management of chronic pulmonary infections. Its revenue guidance for this year is $125M - 135M.
    • Raptor closed Friday at $7.45.
    | Mon, Sep. 12, 7:32 AM | 4 Comments
  • Wed, Sep. 7, 12:13 PM
    • A meta-analysis of all randomized clinical trials of inhaled antibiotics in cystic fibrosis (CF) patients showed Raptor Pharmaceuticals' (RPTP +1.4%) QUINSAIR (aerosolized form of levofloxacin) had similar efficacy to three other inhalable antibiotics in treating lung infections involving the bacterium Pseudomonas aeruginosa, the primary cause of progressive lung function decline in CF sufferers. The data were presented today at the European Respiratory Society International Congress in London.
    • A systematic literature search identified 685 articles, seven studies based on four weeks of follow-up and nine studies based on 24 weeks of follow-up. The performance of levofloxacin was compared to inhaled formulations of tobramycin, colistimethate sodium, aztreonam. An outcomes analysis did not show that the other treatments were more effective than levofloxacin. At 24 weeks, levofloxacin was associated with the lowest risk of hospitalization.
    • QUINSAR, acquired from Tripex Pharmaceuticals in August 2015, was approved in Europe in March 2015 and in Canada three months later. It is not yet available in the U.S.
    | Wed, Sep. 7, 12:13 PM | 2 Comments
  • Thu, Aug. 18, 11:00 AM
    | Thu, Aug. 18, 11:00 AM | 6 Comments
  • Thu, Aug. 18, 9:17 AM
    | Thu, Aug. 18, 9:17 AM
  • Thu, Aug. 18, 8:46 AM
    • Raptor Pharmaceuticals (NASDAQ:RPTP) is ahead 16% premarket on robust volume on the buzz that several companies are eyeing the Novato, CA firm, including Shire plc (NASDAQ:SHPG) who alleged has already bid $800M and Retrophin (NASDAQ:RTRX), founded by biotech bad boy Martin Shkreli.
    • Raptor focuses its development efforts in rare diseases. Its pipeline includes programs in Huntington's disease, cancer, cystic fibrosis and mitochondrial diseases.
    • It currently markets two products: PROCYSBI (cysteamine bitartrate) delayed-release capsules for nephropathic cystinosis and QUINSAIR (aerosolized form of levofloxacin) for the management of chronic pulmonary infections.
    | Thu, Aug. 18, 8:46 AM | 2 Comments
  • Wed, Aug. 17, 5:36 PM
    • Top gainers, as of 5.25 p.m.: NTAP +5.7%. RPTP +5.1%. ARWR +3.5%. ACIA +3.4%. LB +3.3%.
    • Top losers, as of 5.25 p.m.: BGG -14.8%. ARAY -9.6%. KEYS -9.0%. A -5.0%. BHP -4.6%.
    | Wed, Aug. 17, 5:36 PM | 2 Comments
  • Wed, Aug. 17, 10:59 AM
    | Wed, Aug. 17, 10:59 AM
  • Fri, Aug. 12, 8:04 AM
    • TeamHealth Holdings (NYSE:TMH) upgraded to Buy from Hold with a $52 (41% upside) price target by Jefferies.
    • Editas Medicine (NASDAQ:EDIT) upgraded to Buy from Hold with a $35 (69% upside) price target by Jefferies.
    • ZIOPHARM Oncology (NASDAQ:ZIOP) upgraded to Market Perform from Underperform by Wells Fargo. Target price range: $5 - 8 (25% upside from midpoint).
    • Bellicum Pharmaceuticals (NASDAQ:BLCM) upgraded to Buy from Neutral with a $24 (22% upside) price target by Citigroup.
    • Alere (NYSE:ALR) upgraded to Buy from Neutral with a $48 (20% upside) price target by BTIG Research.
    • Merck (NYSE:MRK) upgraded to Outperform from Neutral by Credit Suisse. Price target raised to $73 (15% upside) from $62. Upgraded to Outperform from Market Perform by BMO Capital. Price target raised to $72 (13% upside) from $62.
    • Celgene (NASDAQ:CELG) upgraded to Buy from Neutral with a $138 (21% upside) price target by BTIG Research.
    • Bristol-Myers Squibb (NYSE:BMY) downgraded to Hold from Buy by Berenberg. Price target lowered to $70 (15% upside) from $80. Downgraded to Neutral from Outperform by Credit Suisse. Price target lowered to $63 (3% upside) from $86.
    • Zosano Pharma (NASDAQ:ZSAN) downgraded to Neutral from Buy by Ladenburg Thalmann.
    • Myriad Genetics (NASDAQ:MYGN) downgraded to Hold from Buy by Gabelli & Co. Price target lowered to $32 (54% upside) from $46.
    • Ohr Pharmaceutical (NASDAQ:OHRP) downgraded to Hold from Buy by Brean Capital.
    • Inovio Pharmaceuticals (NASDAQ:INO) downgraded to Hold from Buy by Maxim Group. $14 price target removed.
    • Raptor Pharmaceutical (NASDAQ:RPTP) downgraded to Neutral from Buy by Citigroup. Price target raised to $8 (19% upside) from $6.
    • Regeneron Pharmaceuticals (NASDAQ:REGN) downgraded to Neutral from Outperform by Baird. Price target lowered to $488 (16% upside) from $505.
    | Fri, Aug. 12, 8:04 AM | 7 Comments
  • Thu, Aug. 4, 4:53 PM
    • Raptor Pharmaceutical (NASDAQ:RPTP): Q2 EPS of -$0.13 beats by $0.05.
    • Revenue of $32.05M (+37.4% Y/Y) beats by $3.53M.
    • Press Release
    | Thu, Aug. 4, 4:53 PM
  • Wed, Aug. 3, 5:35 PM
  • Thu, May 5, 5:13 PM
    • Raptor Pharmaceutical (NASDAQ:RPTP): Q1 EPS of -$0.17 in-line.
    • Revenue of $27.47M (+34.3% Y/Y) beats by $0.3M.
    | Thu, May 5, 5:13 PM